IP Library Granted Patent US 8,415,307
Granted Patent B1
US 8,415,307 · App. 13/167,495 · Granted Apr 9, 2013

Antibiotic compositions for the treatment of gram negative infections

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,415,307
App. No.
13/167,495
Granted
Apr 9, 2013
Kind
B1
Abstract

Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.

Claims (20)

1. A pharmaceutical composition comprising an antibacterial compound of the Formula (Ia):

or a pharmaceutically acceptable salt thereof.

2. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

3. The composition of claim 2 , wherein the composition is adapted for inhalation or intravenous administration.

4. The composition of claim 1 , wherein the compound of Formula (Ia) is at least 94% enantiomerically pure.

5. A method of treating a bacterial infection comprising gram-negative bacteria, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula (Ia):

or a pharmaceutically acceptable salt thereof.

6. The method according to claim 5 , wherein the subject is a human, an animal, a cell culture, or a plant.

7. The method according to claim 5 , further comprising the step of determining the species of gram-negative bacteria in the bacterial infection.

8. The method according to claim 5 , wherein the bacterial infection comprises a susceptible or multi-drug resistant bacteria.

9. The method of claim 5 , wherein the bacterial infection comprises Pseudomonas aeruginosa, Acinetobacter spp, Stenotrophomonas maltophilia, Escherichia coli, Klebsiella pneumoniae, Citrobacter spp, Enterobacter spp, or a combination thereof.

10. A process for preparing an antibacterial compound, the process comprising:

a) treating polymyxin A with an amino protecting group comprising at least one acidic substituent to form a protected compound;

b) treating the protected compound with a deacylating agent, to form at least one deacylated protected compound;

c) treating the at least one deacylated protected compound with an activated ester to form at least one acylated protected compound; and

d) treating the at least one acylated protected compound with an organic base to form an antibacterial compound having Formula (Ia):

11. The process of claim 10 , wherein the deacylating agent is produced by Actinoplanes utahensis.

12. The process of claim 10 , wherein the protecting group is 2-sulfo-9-fluorenylmethoxycarbonyl.

13. A compound represented by the Structural Formula (Ia):

or a salt thereof.

Assignments (3)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2015
From: CUBIST PHARMACEUTICALS LLC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036046/0602 →
CHANGE OF NAME Recorded Jul 9, 2015
From: CUBIST PHARMACEUTICALS, INC.
To: CUBIST PHARMACEUTICALS LLC
Reel/Frame 036084/0448 →